MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jnci/djv179

Медицинская библиотека · Journal of the National Cancer Institute · 2015

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

Ligibel Jennifer A, Cirrincione Constance T, Liu Minetta, Citron Marc, Ingle James N, Gradishar William, Martino Silvana, Sikov William, Michaelson Richard, Mardis Elaine, Perou Charles M, Ellis Matthew, Winer Eric, Hudis Clifford A, Berry Donald, Barry William T

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Obesity at diagnosis is associated with poor prognosis in women with breast cancer, but few reports have been adjusted for treatment factors.

METHODS

CALGB 9741 was a randomized trial of dose density and sequence of chemotherapy for node-positive breast cancer. All patients received doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight. Height and weight at diagnosis were abstracted from patient records, and the PAM50 assay was performed from archived specimens using the NanoString platform. Relationships between body mass index (BMI), PAM50, and recurrence-free and overall survival (RFS and OS) were evaluated using proportional hazards regression, adjusting for number of involved nodes, estrogen receptor (ER) status, tumor size, menopausal status, drug sequence, and dose density. All statistical tests were two-sided.

RESULTS

Baseline height and weight were available for 1909 of 2005 enrolled patients; 1272 additionally had subtype determination by PAM50. Median baseline BMI was 27.4kg/m(2). After 11 years of median follow-up, there were 619 RFS events and 543 deaths. Baseline BMI was a statistically significant predictor of RFS (adjusted hazard ratio [HR] for each five-unit increase in BMI = 1.08, 95% confidence interval [CI] = 1.02 to 1.14, P = .01) and OS (adjusted HR = 1.08, 95% CI = 1.01 to 1.14, P = .02) BMI and molecular phenotypes were independent prognostic factors for RFS, with no statistically significant interactions detected.

CONCLUSIONS

BMI at diagnosis was a statistically significant prognostic factor in a group of patients receiving optimally dosed chemotherapy. Additional research is needed to determine the impact of weight loss on breast cancer outcomes and to evaluate whether this impact is maintained across tumor subtypes.

Для цитирования: Ligibel Jennifer A, Cirrincione Constance T, Liu Minetta, Citron Marc, Ingle James N, Gradishar William, Martino Silvana, Sikov William, Michaelson Richard, Mardis Elaine, Perou Charles M, Ellis Matthew, Winer Eric, Hudis Clifford A, Berry Donald, Barry William T. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).. Journal of the National Cancer Institute. 2015. DOI: 10.1093/jnci/djv179.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.